ketamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1523	6740-88-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ketamine narketan (+/-)-Ketamine ketamine hydrochloride ketamine HCl	A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. Molecular weight: 237.73 Formula: C13H16ClNO CLOGP: 2.93 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 29.10 ALOGS: -3.71 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ketamine
narketan
(+/-)-Ketamine
ketamine hydrochloride
ketamine HCl

A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.

Molecular weight: 237.73
Formula: C13H16ClNO
CLOGP: 2.93
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 29.10
ALOGS: -3.71
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	8.41 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
EoM (Fraction excreted unchanged in urine)	4 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	200 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.90 L/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.80 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	19 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.47 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Feb. 19, 1970	FDA	PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	596.75	24.78	205	11149	23428	63454240
Drug ineffective for unapproved indication	172.40	24.78	95	11259	33968	63443700
Propofol infusion syndrome	171.92	24.78	39	11315	944	63476724
Body tinea	170.77	24.78	44	11310	1841	63475827
Inhibitory drug interaction	148.32	24.78	43	11311	2806	63474862
Infection susceptibility increased	143.57	24.78	44	11310	3477	63474191
Dilatation intrahepatic duct acquired	140.66	24.78	31	11323	655	63477013
Multiple-drug resistance	138.66	24.78	47	11307	5123	63472545
Bronchospasm	133.21	24.78	64	11290	17216	63460452
Mitochondrial DNA mutation	131.86	24.78	27	11327	395	63477273

Showing 1 to 10 of 137 entries

Previous1 2 3 4 5…14Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	536.34	22.31	195	10197	15746	34930793
Drug abuse	200.54	22.31	193	10199	98903	34847636
Drug ineffective	192.87	22.31	419	9973	456332	34490207
Sedation	186.80	22.31	101	10291	20905	34925634
Nightmare	144.32	22.31	75	10317	14316	34932223
Cystitis ulcerative	128.20	22.31	18	10374	0	34946539
Hypotension	124.72	22.31	230	10162	221419	34725120
Anaphylactic reaction	95.21	22.31	78	10314	32223	34914316
Product used for unknown indication	91.02	22.31	26	10366	957	34945582
Nephrolithiasis	90.98	22.31	74	10318	30259	34916280

Showing 1 to 10 of 94 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	1102.69	18.94	398	20595	35598	79687797
Drug abuse	288.01	18.94	279	20714	162412	79560983
Drug ineffective	279.70	18.94	763	20230	1080150	78643245
Hypotension	213.30	18.94	400	20593	439917	79283478
Bronchospasm	204.39	18.94	109	20884	24750	79698645
Hydronephrosis	197.54	18.94	95	20898	17359	79706036
Propofol infusion syndrome	187.85	18.94	52	20941	1931	79721464
Drug ineffective for unapproved indication	187.50	18.94	134	20859	51104	79672291
Anaphylactic reaction	175.67	18.94	158	20835	83585	79639810
Cystitis ulcerative	166.59	18.94	23	20970	0	79723395

Showing 1 to 10 of 214 entries

Previous1 2 3 4 5…22Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N01AX03	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Other general anesthetics
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:38877	intravenous anesthetics
CHEBI has role	CHEBI:50910	agente neurotoxico
CHEBI has role	CHEBI:60643	N-methyl-D-aspartate receptor antagonists
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000175681	General Anesthetic
FDA PE	N0000175975	General Anesthesia
MeSH PA	D000700	Analgesics
MeSH PA	D000777	Anesthetics

Showing 1 to 10 of 18 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Local anesthesia	indication	386761002
Pain	off-label use	22253000
Inflammatory disease of mucous membrane	off-label use	95361005
Major depressive disorder	off-label use	370143000
Delirium	contraindication	2776000
Ocular hypertension	contraindication	4210003	DOID:9282
Alcoholism	contraindication	7200002
Myocardial infarction	contraindication	22298006	DOID:5844
Alcohol intoxication	contraindication	25702006

Showing 1 to 10 of 23 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Cats	Restraint	Indication
Cats	Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation	Indication
Primates	Restraint	Indication
Primates	Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation	Indication

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary products

Show entries

Search:

Product	Applicant	Ingredients
Ketamine HCL	Mylan Institutional LLC, a Viatris Company	1
Ketamine Hydrochloride Injection	Cronus Pharma Specialities India Private Limited	1
Ketamine Hydrochloride Injection, USP	Elanco US Inc.	1
Ketamine Hydrochloride Injection, USP	Dechra Veterinary Products LLC	1
Ketaset	Zoetis Inc.	1
Ketaset Plus	Zoetis Inc.	3
Ketaset, Vetalar	Boehringer lngelheim Animal Health USA Inc.	1
VetaKet	Akorn Animal Health Inc.	1

Showing 1 to 8 of 8 entries

Previous1Next

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glutamate [NMDA] receptor	Ion channel	O15399 O60391 Q05586 Q12879 Q13224 Q14957 Q8TCU5	NMDE4_HUMAN NMD3B_HUMAN NMDZ1_HUMAN NMDE1_HUMAN NMDE2_HUMAN NMDE3_HUMAN NMD3A_HUMAN	BLOCKER	Ki	6.38	CHEMBL	CHEMBL
Glutamate receptor ionotropic AMPA	Ion channel	P42261 P42262 P42263 P48058	GRIA1_HUMAN GRIA2_HUMAN GRIA3_HUMAN GRIA4_HUMAN	OPENER			SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Acetylcholine receptor subunit alpha	Ion channel		ACHA_TORCA		IC50	5.31	CHEMBL
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT		IC50	6.21	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
001403	NDDF
004581	NDDF
1867-66-9	SECONDARY_CAS_RN
203184	RXNORM
2156	INN_ID
31706007	SNOMEDCT_US
333847008	SNOMEDCT_US
373464007	SNOMEDCT_US
3821	PUBCHEM_CID
4018154	VANDF

Showing 1 to 10 of 25 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KETALAR	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9880	INJECTION	10 mg	INTRAVENOUS	NDA	17 sections
KETALAR	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9880	INJECTION	10 mg	INTRAVENOUS	NDA	17 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-113	INJECTION	10 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-113	INJECTION	10 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-114	INJECTION	50 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-114	INJECTION	50 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-115	INJECTION	100 mg	INTRAMUSCULAR	NDA	27 sections
Ketalar	HUMAN PRESCRIPTION DRUG LABEL	1	42023-115	INJECTION	100 mg	INTRAMUSCULAR	NDA	27 sections
KETALAR	HUMAN PRESCRIPTION DRUG LABEL	1	52584-037	INJECTION	10 mg	INTRAVENOUS	NDA	19 sections
KETALAR	HUMAN PRESCRIPTION DRUG LABEL	1	52584-037	INJECTION	10 mg	INTRAVENOUS	NDA	19 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next